GEAN Stock Overview
A science-based diagnostic company, develops diagnostic solutions for human microbiome market. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genetic Analysis AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.52 |
| 52 Week High | NOK 1.75 |
| 52 Week Low | NOK 0.27 |
| Beta | 1.72 |
| 1 Month Change | 2.36% |
| 3 Month Change | -16.67% |
| 1 Year Change | -22.16% |
| 3 Year Change | -89.60% |
| 5 Year Change | n/a |
| Change since IPO | -94.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEAN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 13.0% | -1.7% | -0.3% |
| 1Y | -22.2% | 13.7% | 12.6% |
Return vs Industry: GEAN underperformed the Swedish Biotechs industry which returned 13.7% over the past year.
Return vs Market: GEAN underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| GEAN volatility | |
|---|---|
| GEAN Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: GEAN's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: GEAN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 21 | Ronny Hermansen | www.genetic-analysis.com |
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market. It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-map Dysbiosis Test reagent kit, a CE-IVD documented test, which is a software that performs QC on the run file, calculates the dysbiosis index score and abundance table, and converts sample result into reports; and GA-map Covid fecal test reagent kit, a CE-IVD documented test to detect SARS-CoV-2 in fecal samples. The company has a strategic agreement to develop and launch a new rapid microbiome-based PCR test.
Genetic Analysis AS Fundamentals Summary
| GEAN fundamental statistics | |
|---|---|
| Market cap | NOK 25.68m |
| Earnings (TTM) | -NOK 20.51m |
| Revenue (TTM) | NOK 19.71m |
1.3x
P/S Ratio-1.3x
P/E RatioIs GEAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEAN income statement (TTM) | |
|---|---|
| Revenue | NOK 19.71m |
| Cost of Revenue | NOK 3.68m |
| Gross Profit | NOK 16.03m |
| Other Expenses | NOK 36.55m |
| Earnings | -NOK 20.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 81.35% |
| Net Profit Margin | -104.06% |
| Debt/Equity Ratio | 20.5% |
How did GEAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 03:46 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genetic Analysis AS is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gediminas Ruginis | Norne Securities AS |